AD 215
Alternative Names: AD-215Latest Information Update: 16 Dec 2020
At a glance
- Originator Addpharma
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Gastritis
Most Recent Events
- 16 Dec 2020 AD 215 is available for licensing as of 16 Dec 2020. http://www.addpharma.co.kr/
- 16 Dec 2020 Early research in Gastritis in South Korea (unspecified route) (Addpharma pipeline, December 2020)